An Exploratory Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess Mechanism Of Action (MOA) Of CP-690,550 In The Skin When Administered Orally At 10 Mg Twice Daily (BID) For 12 Weeks In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Trial Profile

An Exploratory Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess Mechanism Of Action (MOA) Of CP-690,550 In The Skin When Administered Orally At 10 Mg Twice Daily (BID) For 12 Weeks In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Apr 2016 Results published in the Journal of Allergy and Clinical Immunology
    • 23 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Oct 2013 Planned end date changed from 1 Sep 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top